# NEST3 (NCT07595874)

> Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07595874
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: City of Hope Medical Center
- Conditions: Advanced Colon Adenocarcinoma; Advanced Colorectal Adenocarcinoma; Advanced Rectal Adenocarcinoma; Stage IIB Colon Cancer AJCC v8; Stage IIB Rectal Cancer AJCC v8; Stage IIC Colon Cancer AJCC v8; Stage IIC Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8
- Interventions: Balstilimab; Biospecimen Collection; Botensilimab; Computed Tomography; Magnetic Resonance Imaging
- Enrollment: 100
- Primary outcome: Two-year disease-free survival rate

## Commentary we found

- X threads: 9
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nest3-nct07595874

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07595874", "email": "<work email>"}; the inbox owner confirms by the emailed link.